StemCell Therapy

WALTHAM, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the Company will host a virtual key opinion leader (KOL) event on Monday, December 11, at 8:00 a.m. ET to discuss highlights from its poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. Following the prepared remarks, the call will be opened for a live question and answer session. To submit a question, please reach out to questions@lifesciadvisors.com.

See the rest here:
TScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual...

SOUTH SAN FRANCISCO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on Wednesday, December 6, 2023 at 2:30 p.m. ET / 11:30 a.m. PT.

Go here to read the rest:
Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit

Daix (France), Long Island City (New York, United States), December 4, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced the positive recommendation from the third meeting of the Data Monitoring Committee (DMC) to continue the NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH without modification to the trial protocol. The DMC, composed of a group of independent experts, arrived at this recommendation after review of the safety data of patients enrolled in the NATiV3 trial.

See the rest here:
Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH

-Based on preliminary data from ongoing clinical trials, focusing on next-generation CAR T product candidates, CTX112™ targeting CD19 and CTX131™ targeting CD70-

See the article here:
CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease

Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15

Read more from the original source:
Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15

PARIS and CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces today the closing of the previously announced subscription by Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”) for 901,256 additional ordinary shares of the Company, in the form of restricted American Depositary Shares (“ADSs”), for an aggregate amount of $4.8 million, equivalent to €4.6 million1 (the “Remaining Placement Amount”, and the subscription transaction being the “Remaining Placement”), following the approval by the French Ministry of Economy of JJDC Remaining Placement on November 22, 2023, in accordance with the French foreign investment control rules2.

See the rest here:
Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.

FOSTER CITY, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (“Notable”) (Nasdaq: NTBL), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today announced that Thomas Bock, M.D., CEO of Notable Labs, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit taking place virtually on December 5 – 6, 2023.

See the original post:
Notable Labs to Participate in JMP Securities Hematology and Oncology Summit

Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023

Original post:
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023  

MELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be hosting an investor webcast on Wednesday, 6 December 2023 in Australia / Tuesday, 5 December 2023 in the United States. Details are listed below and registration is required.

Read the original post:
Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS

Excerpt from:
Avicanna Announces Closing of Non-Brokered Private Placement

-- In the Study, VAX-24 Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) at all Doses Studied ---- All 24 Serotypes of VAX-24 at Conventional 2.2 mcg PCV Dose Met or Exceeded Regulatory Immunogenicity Standards --

Read the original post:
VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent...

Basel, 5 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance®) and fulvestrant as a potential first-line treatment option for people with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer. The study met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant and clinically meaningful improvement compared to palbociclib and fulvestrant alone. Overall survival data were immature at this time, but a clear positive trend has been observed. Follow-up will continue to the next analysis.

The rest is here:
Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer...

Press Release

Read more:
Mendus to present at Cell & Gene Therapy Manufacturing & Commercialization Conference in Dublin on December 4-6

SIENA, Italy, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Philogen S.p.A. (BIT:PHIL) is pleased to announce that its new GMP facility located in Rosia Siena, is now GMP certified. The certification was granted by the GMP MED office of the Agenzia Italiana del Farmaco (AIFA) following an inspection occurred in July 2023. AIFA confirmed that Philogen new facility complies with the requirements and guidelines of Good Manufacturing Practice outlined in the Directive 2003/94/EC issued by the European Parliament.

Here is the original post:
Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate for its new Production facility in Rosia (Siena, Italy) by Competent...

Breast Cancer Is Most Common Cancer In India, 1.38 Million Cases Diagnosed Annually. Know Estimated Incidence By 2030  ABP Live

Go here to see the original:
Breast Cancer Is Most Common Cancer In India, 1.38 Million Cases Diagnosed Annually. Know Estimated Incidence By 2030 - ABP Live

Mom who homeschools her children reveals she lets her one-year-old play in and EAT mud - but insists it is goo  Daily Mail

Here is the original post:
Mom who homeschools her children reveals she lets her one-year-old play in and EAT mud - but insists it is goo - Daily Mail

The limits of nutritional supplements: they dont cure or prevent ailments, nor are they harmless  EL PAS USA

Original post:
The limits of nutritional supplements: they dont cure or prevent ailments, nor are they harmless - EL PAS USA

YARDLEY, Pa., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the 35th Annual Piper Sandler Healthcare Conference on November 29, 2023, at 3:30 p.m. ET.

View original post here:
Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference

Virtual Event to be held on November 29, 2023 at 4:15 p.m. ET Virtual Event to be held on November 29, 2023 at 4:15 p.m. ET

More here:
Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis

BAUDETTE, Minn., Nov. 22, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President & CEO, will participate at the Piper Sandler 35th Annual Healthcare Conference in New York City as follows:

Here is the original post:
ANI Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference